Understand the complete drug development lifecycle from Phase 1 safety studies through Phase 4 post-market surveillance.
Preclinical Development & IND
15 min
Before Human Testing: Preclinical Development
Before any investigational drug, biologic, or device can be tested in humans, it must undergo rigorous preclinical evaluation. This phase bridges laboratory discovery with clinical application.
Preclinical Studies
In Vitro Studies: Laboratory testing using cell cultures, tissue samples, or biochemical assays to evaluate the compound's mechanism of action, potency, and selectivity.
In Vivo Studies: Animal studies (typically rodent and non-rodent species) to assess pharmacokinetics (absorption, distribution, metabolism, excretion — ADME), pharmacodynamics, and preliminary safety/toxicology.
Manufacturing: Development of Good Manufacturing Practice (GMP) processes to produce clinical-grade material.
The IND/CTA Application
To begin human testing, the sponsor must submit an Investigational New Drug (IND) application (FDA) or Clinical Trial Authorization (CTA) application (EMA/local authority).
Chemistry, Manufacturing, and Controls (CMC): Drug composition, manufacturing process, stability data, and quality specifications.
Preclinical Data: All pharmacology and toxicology data supporting the proposed first-in-human dose.
Clinical Protocol: The detailed plan for the proposed clinical trial.
Investigator's Brochure (IB): Summary of all known data about the investigational product.
The FDA has 30 days to review an IND before the study can proceed (unless a clinical hold is issued).
